<DOC>
	<DOCNO>NCT00708812</DOCNO>
	<brief_summary>In randomize , double-blind , placebo-controlled , multicentre trial , 126 patient July 5 , 2007 July 30 , 2008 enrol 10 center . The leader unit Shanghai Chest Hospital Affiliated Shanghai Jiao-Tong University Shanghai Changzheng Hospital . All eligible patient receive 1 cycle ( 21 day ) TC chemotherapy . After chemotherapy , patient evaluate SD ( Stable Disease ) randomize receive endostar plus TC TC alone 3 cycle , 21 day one cycle .</brief_summary>
	<brief_title>Paclitaxel Plus Carboplatin With Without Endostar Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>histologically cytologically confirm , previously untreated stage IIIB IV NSCLC age 1875 year least one measurable lesion ( RECIST ) patient evaluate SD 1 cycle ( 21 day ) TC chemotherapy . adequate hematologic , cardiac , renal , hepatic function ECOG PS 02 symptomatic brain metastasis bone metastasis complication major organ dysfunction bleed diathesis coagulopathy pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Endostar</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
</DOC>